Summary of Product Characteristics (SmPC) - Metronidazole 500 mg tablets
1 NAME OF THE MEDICINAL PRODUCT
Metronidazole 500 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 500 mg of metronidazole.
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Film-coated tablets.
White to off white colored, round convex shaped (approx. 13.00 mm) film coated tablets, debossed “500” on one side and plain on the other side.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Metronidazole is indicated in the prophylaxis and treatment of infections in which anaerobic bacteria have been identified or are suspected to be the cause.
Metronidazole is active against a wide range of pathogenic microorganisms, notably species of Bacteroides, Fusobacteria, Clostridia, Eubacteria, anaerobic cocci and Gardnerella vaginalis.
It is also active against Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia, Balantidium coli and Helicobacter pylori.
Metronidazole is indicated in adults and children for the following indications:
- Prevention of post-operative infections due to anaerobic bacteria, particularly species of bacteroides and anaerobic streptococci.
- The treatment of septicaemia, bacteraemia, peritonitis, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and post-operative wound infections from which pathogenic anaerobes have been isolated.
- Urogenital trichomoniasis in the female (Trichomonas vaginalis), and in man.
Bacterial vaginosis (also known as non-specific vaginitis, anaerobic vaginosis or
Gardnerella vaginalis).
- All forms of amoebiasis (intestinal and extra-intestinal disease and asymptomatic cyst passers).
- Treatment of Helicobacter pylori infection associated with peptic ulcer as part of triple therapy.
- Giardiasis.
- Acute ulcerative gingivitis.
- Anaerobically-infected leg ulcers and pressure sores.
- Acute dental infections (e.g. acute pericoronitis and acute apical infections). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
4.2 Posology and method of administration
Posology
Metronidazole tablets should be taken during or after meals, swallowed with water and not chewed.
Elderly
Caution is advised in the elderly, particularly at high doses, although there is limited information available on modification of dosage.
Hepatic impairment
Caution is advised in patients with hepatic encephalopathy. One third of the daily dose given once a day should be considered (see section 4.4).
- 1) Anaerobic infections
Treatment for 7 days should be satisfactory for most patients but, depending upon clinical and bacteriological assessments, the physician may decide to prolong treatment, e.g. for eradication of infection from sites which cannot be drained or are liable to endogenous recontamination by anaerobic pathogens from the gut, oropharynx or genital tract.
Children >8 weeks to 12 years of age
The usual daily dose is 20-30 mg/kg/day as a single dose or divided into 7.5 mg/kg every 8 hours. The daily dose may be increased to 40 mg/kg, depending on the severity of the infection. Duration of treatment is usually 7 days.
Children <8 weeks of age
15 mg/kg as a single dose daily or divided into 7.5 mg/kg every 12 hours.
Newborns with a gestation age <40 weeks
Accumulation of metronidazole can occur during the first week of life, therefore the concentrations of metronidazole in serum should preferably be monitored after a few days therapy.
Children under 10 years
A more suitable dosage form should be used for this age group.
Prophylaxis against anaerobic infection
Chiefly in the context of abdominal (especially colorectal) and gynaecological surgery.
Adults
1 g stat dose 24 hours pre-operatively, followed by 400 mg at 8 hourly intervals during the 24 hours preceding operation followed by post-operative iv or rectal administration until the patient is able to take tablets.
Children <12 years
20-30 mg/kg as a single dose given 1-2 hours before surgery.
Newborns with a gestation age <40 weeks
10 mg/kg body weight as a single dose before operation.
Children under 10 years
A more suitable dosage form should be used for this age group.
- 2) Treatment of established infections
Adults and children over 10 years
800 mg followed by 400 mg 8 hourly.
Children under 10 years
A more suitable dosage form should be used for this age group.
- 3) Urogenital trichomoniasis
Where reinfection is likely, sexual partners should be treated concomitantly.
Adults and adolescents
2000 mg as a single dose or 200 mg 3 times daily for 7 days or 400 mg twice daily for 5-7 days.
Children < 10 years
40 mg/kg orally as a single dose or 15 – 30 mg/kg/day divided in 2-3 doses for 7 days; not to exceed 2000 mg/dose.
Children under 10 years
A more suitable dosage form should be used for this age group.
- 4) Bacterial vaginosis
Adults
400 mg twice daily for 7 days, or 2g as a single dose for one day only.
Adolescents
400 mg twice daily for 5-7 days or 2000 mg as a single dose.
- 5) Amoebiasis
Adults
400 to 800 mg 3 times daily for 5-10 days.
Children 7 to 10 years
200 to 400 mg 3 times daily for 5-10 days.
Children 3 to 7 years
100 to 200 mg 4 times daily for 5-10 days.
Children 1 to 3 years
100 to 200 mg 3 times daily for 5-10 days.
Alternatively, doses may be expressed by body weight: 35 to 50 mg/kg daily in 3 divided doses for 5 to 10 days, not to exceed 2400 mg/day.
Children under 7 years
A more suitable dosage form should be used for this age group.
- 6) Giardiasis
Adults
2000 mg once daily for 3 days, or 400 mg. three times daily for 5 days, or 500 mg twice daily for 7 to 10 days.
Children 7 to 10 years
1000 mg once daily for 3 days.
Children 3 to 7 years
600 to 800 mg once daily for 3 days.
Children 1 to 3 years
500 mg once daily for 3 days.
Alternatively, as expressed in mg per kg of body weight
15-40 mg/kg/day divided in 2-3 doses.
Children under 7 years
A more suitable dosage form should be used for this age group.
- 7) Acute ulcerative gingivitis (for 3 day duration)
Adults and children over 10 years
200 mg three times daily.
Children under 10 years
A more suitable dosage form should be used for this age.
- 8) Acute dental infections (for 3-7 day duration)
Adults and children over 10 years
200 mg three times daily.
- 9) Leg ulcers and pressure sores (for 7 day duration)
Adults and children over 10 years
400 mg three times daily.
- 10) Treatment of Helicobacter pylori in infected patients
As a part of a combination therapy, 20 mg/kg/day not to exceed 500 mg twice daily for 7-14 days. Official guidelines should be consulted before initiating therapy.
Method of Administration
For oral administration.
4.3 Contraindications
- Known hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Pregnancy - metronidazole should not be used in the first trimester in patients with trichomoniasis or bacterial vaginosis (see section 4.6).
Breast feeding should be discontinued for 12-24 hours when single high dose (e.g. 2 g)
therapy is used (see section 4.6).
4.4 Special warnings and precautions for use
Patients should abstain from alcohol for at least 48 hours following discontinuation of therapy with metronidazole. A disulfiram-like reaction with hypotension and flushing has occurred (see section 4.5).
Caution is advised in patients with porphyria.
Metronidazole tablets should not be used in patients with blood dyscrasias or with active non-infectious disease of the central nervous system. High doses of metronidazole may mask the presence of syphilis.
Caution in patients with epilepsy or those who have had seizures as high doses of metronidazole can induce seizures.
Use with caution in the second and third trimester when used to treat trichomoniais or bacterial vaginosis (see section 4.6.)
There is a possibility that after Trichomonas vaginalis has been eliminated a gonococcal infection might persist.
The elimination half-life of metronidazole remains unchanged in the presence of renal failure. The dosage of metronidazole, therefore, needs no reduction. Such patients, however, retain the metabolites of metronidazole. The clinical significance of this is not known at present. In patients undergoing haemodialysis metronidazole and metabolites are efficiently removed during an eight-hour period of dialysis. Metronidazole should, therefore, be readministered immediately after haemodialysis.
No routine adjustment in the dosage of metronidazole need be made in patients with renal failure undergoing intermittent peritoneal dialysis (IPD) or continuous ambulatory peritoneal dialysis (CAPD).
Metronidazole is mainly metabolised by hepatic oxidation. Substantial impairment of metronidazole clearance may occur in the presence of advanced hepatic insufficiency. Significant accumulation may occur in patients with hepatic encephalopathy and the resulting high plasma concentrations of metronidazole may contribute to symptoms of the encephalopathy. Therefore, metronidazole should be administered with caution to patients with hepatic encephalopathy. The daily dosage should be reduced to one third and may be administered once daily.
Patients should be warned that metronidazole may darken urine. For information on renal and hepatic insufficiency, please see section 4.2.
Due to inadequate evidence on the mutagenicity risk in humans, the use of metronidazole for longer treatment than usually required should be carefully considered.
Neuropathy (central and peripheral)
Regular clinical and laboratory monitoring (especially leucocyte count) are advised if administration of metronidazole for more than 10 days is considered to be necessary and patients should be monitored for adverse reactions such as peripheral or central neuropathy (such as paraesthesia, ataxia, dizziness, vertigo, convulsive seizures).
Metronidazole should be used with caution in patients with active or chronic severe peripheral and central nervous system disease due to the risk of neurological aggravation.
Hepatoxicity in patients with Cockayne syndrome
Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use. In this population, metronidazole should not be used unless the benefit is considered to outweigh the risk and if no alternative treatment is available. Liver function tests must be performed just prior to the start of therapy, throughout and after end of treatment until liver function is within normal ranges, or until the baseline values are reached. If the liver function tests become markedly elevated during treatment, the drug should be discontinued.
Patients with Cockayne syndrome should be advised to immediately report any symptoms of potential liver injury to their physician and stop taking metronidazole (see section 4.8).
Skin and subcutaneous tissue disorders
Cases of severe bullous skin reactions such as Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalised exanthematous pustulosis (AGEP) have been reported with metronidazole. If symptoms or signs of SJS, TEN or AGEP are present, Metronidazole treatment must be immediately discontinued.
4.5 Interaction with other medicinal products and other forms of interaction
Combinations to be used with caution
Lithium
Lithium retention accompanied by evidence of possible renal damage has been reported in patients treated simultaneously with lithium and metronidazole. Lithium treatment should be tapered or withdrawn before administering metronidazole. Plasma concentration of lithium, creatinine, and electrolytes should be monitored in patients under treatment with lithium while they receive metronidazole.
Anticoagulants
Some potentiation of anticoagulant therapy has been reported when metronidazole has been used with the warfarin type oral anticoagulants. Dosage of the latter may require reducing. Prothrombin times should be monitored. No interactions have been reported with anticoagulants of the heparin type. However, anticoagulant activity should be routinely monitored with these products.
Alcohol
Patients should be advised not to take alcohol during metronidazole therapy and for at least 48 hours after because of the possibility of a disulfiram-like (antabuse effect) reaction. Disulfiram: Psychotic reactions have been reported in patients who were using metronidazole and disulfiram concurrently.
Immunosuppressants: Patients receiving ciclosporin are at risk of elevated ciclosporin serum levels. Serum ciclosporin and serum creatinine should be closely monitored when coadministration is necessary.
Pharmacokinetic interactions
Antiepileptics
Patients receiving phenobarbital metabolise metronidazole at a much greater rate than normally, reducing the half-life to approximately 3 hours. Metronidazole inhibits metabolism of phenytoin (increases plasma-phenytoin concentration). Primidone accelerates the metabolism of Metronidazole causing reduced plasma concentrations.
Cytotoxics
Metronidazole inhibits metabolism of fluorouracil. Therefore, increased toxicity of fluorouracil can result. Plasma levels of busulfan may be increased by metronidazole which may lead to severe busulfan toxicity.
Ulcer-healing drugs
Cimetidine inhibits the metabolism of metronidazole (increases plasma-metronidazole concentration).
Oestrogens
Broad spectrum antibiotics possibly reduce the contraceptive effect.
Drug-lab modifications
Aspartate amino transferase assays may give spuriously low values in patients taking metronidazole, depending on the method used.
Busulfan
Plasma levels of busulfan may be increased by metronidazole which may lead to severe busulfan toxicity.
Drugs that prolong QT interval
QT prolongation has been reported, particularly when metronidazole was administered with drugs with potential for prolonging the QT interval.
4.6 Fertility, pregnancy and lactation
As with all medicines, metronidazole should not be given during pregnancy or during lactation unless it is considered essential, and in these circumstances the short, high-dosage regimens are not recommended.
Pregnancy
Metronidazole is contraindicated in the first trimester (see section 4.3) and should be used with caution in the second and third trimester when used to treat trichomoniais or bacterial vaginosis (see section 4.4).
For all other indications metronidazole should only be used if the benefits outweigh the risks or no other alternative is available especially in the first trimester.
Breast-feeding
It is advisable to stop breast feeding until 12 – 24 hours after metronidazole therapy has been discontinued (see section 4.3).
4.7 Effects on ability to drive and use machines
Patients should be warned about the potential for drowsiness, dizziness, vertigo, confusion, hallucinations, convulsions or transient visual disorders, and advised not to drive or operate machinery if these symptoms occur.
4.8 Undesirable effects
Frequency type and severity of adverse reactions in children are the same as in adults. The frequency of adverse events listed below is defined using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Serious adverse reactions occur rarely with standard recommended regimes.
Frequency, type and severity of adverse reactions in children are the same as in adults. Clinicians who contemplate continuous therapy for the relief of chronic conditions, for periods longer than those recommended, are advised to consider the possible therapeutic benefit against the risk of peripheral neuropathy.
| Blood and lymphatic system disorders | |
| Very rare | Agranulocytosis, neutropenia, thrombocytopenia, pancytopenia |
| Not known | Leukopenia, bone marrow depression disorders such as aplastic anaemia |
| Immune system disorders | |
| Rare | Anaphylaxis |
| Not known | Angioedema, urticaria, fever |
| Metabolism and nutrition disorders | |
| Not known | Anorexia |
| Psychiatric disorders | |
| Very rare | Psychotic disorders, including confusion and hallucinations |
| Not known | Depressed mood |
| Nervous system disorders | |
| Very rare | Encephalopathy (e.g. confusion, fever, vertigo, headache, hallucinations, paralysis, light sensitivity, disturbances in sight and movement, stiff neck) and subacute cerebellar syndrome (eg. ataxia, dysarthria, gait impairment, nystagmus and tremor) which may resolve on discontinuation of the drug. Drowsiness, dizziness, convulsions, headaches |
| Not known | Depression, paraesthesia, during intensive and-or prolonged metronidazole therapy, peripheral sensory neuropathy or transient epileptiform seizures have been reported. In most cases neuropathy disappeared after treatment was stopped or when dosage was reduced. Incoordination of movement |
| Eye disorders | |
| Very rare | Vision disorders such as diplopia and myopia, which in most cases is transient |
| Not known | Optic neuropathy/neuritis |
| Ear and labyrinth disorders | |
| Not known | Hearing impaired/hearing loss (including sensorineural), tinnitus |
| Cardiac disorders | |
| Not known | QT prolongation has been reported particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. |
| Gastrointestinal disorders | |
| Not known | Unpleasant taste in the mouth, taste disorders, oral mucositis, furred tongue, nausea, vomiting, gastrointestinal disturbances such as diarrhoea, epigastric pain, anorexia |
| Hepatobiliary disorders | |
| Very rare | Increase in liver enzymes (AST, ALT, alkaline phosphatase), cholestatic or mixed hepatitis and hepatocellular liver injury, jaundice and pancreatitis which is reversible on drug withdrawal. Cases of liver failure requiring liver transplant have been reported in patients treated with metronidazole in combination with other antibiotic drugs |
| Skin and subcutaneous tissue disorders | |
| Very rare | Skin rashes, pustular eruptions, acute generalised exanthematous pustulosis (AGEP), pruritus, flushing |
| Not known | Erythema multiforme, Steven-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), fixed |
| drug eruption | |
| Musculoskeletal, connective tissue and bone disorders | |
| Very rare | Myalgia, arthralgia |
| Renal and urinary disorders | |
| Very rare | Darkening of urine (due to metronidazole metabolite) |
Cases of severe irreversible hepatotoxicity/acute liver failure, including cases with fatal outcomes with very rapid onset after initiation of systemic use of metronidazole, have been reported in patients with Cockayne Syndrome (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Features
Nausea, vomiting, diarrhoea, anorexia, metallic taste, headache, dizziness and occasionally insomnia and drowsiness. Transiently increased liver enzyme activities have been reported rarely.
Transient epileptiform seizures have been reported following intensive or prolonged therapy. Other adverse effects occurring in these circumstances include peripheral motor neuropathy, blood dyscrasias and liver damage.
The combination of alcohol and metronidazole has been said to cause disulfiram type reactions in about 10% of individuals with sudden onset of excitement, giddiness, flushing, nausea, headache, hypotension and dyspnoea. However the mechanism of this reaction has been questioned.
Treatment
Unlikely to be required.
Disulfiram type reactions should be treated with intravenous fluids and plasma expanders if necessary. Symptomatic and supportive.
In more serious cases:
- 1. Single brief convulsions do not require treatment. If frequent or prolonged control with intravenous diazepam (10- 20 mg in adults; 0.1-0.3mg/kg body weight) or lorazepam (4mg in an adult and 0.05mg/kg in a child). Give oxygen and correct acid base and metabolic disturbances as required.
- 2.
Other measures as indicated by the patient's clinical condition.
Single oral doses of metronidazole, up to 12 g have been reported in suicide attempts and accidental overdoses. Symptoms were limited to vomiting, ataxia and slight disorientation. There is no specific antidote for metronidazole overdosage. In cases of suspected massive overdose, symptomatic and supportive treatment should be instituted.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Nitroimidazole derivatives, ATC code: P01AB01.
Mechanism of action
Metronidazole has antiprotozoal and antibacterial effects. It is effective against Trichomonas vaginalis, Gardnerella vaginalis and other protozoa including Entamoeba histolytica and Giardia lamblia, and against anaerobic bacteria.
5.2 Pharmacokinetic properties
Absorption
Metronidazole is readily absorbed following administration by mouth and bioavailability is 90-100%. Peak plasma concentrations of approximately 5μg/ml and 10μg/ml are achieved an average of 1-2 hours after single doses of 250mg and 500mg respectively. Some accumulation and consequently higher concentrations occur when multiple doses are given. Absorption may be delayed, but is not reduced overall, by administration with food.
Distribution
Metronidazole is widely distributed. It appears in most body tissues and fluids. It also crosses the placenta and rapidly enters foetal circulation. No more than 20% is bound to plasma proteins.
Biotransformation
Metronidazole is metabolised in the liver by side-chain oxidation and glucuronide formation. The plasma elimination half-life of metronidazole is about 6-9 hours; that of the hydroxy metabolite is slightly longer. The half-life of metronidazole is reported to be longer in neonates and in patients with severe liver disease.
Elimination
The majority of a dose of metronidazole is excreted in the urine, mainly as metabolites; a small amount appears in the faeces.
5.3 Preclinical safety data
None.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Anhydrous calcium hydrogen phosphate (E341)
Pregelatinized maize starch
Povidone (PVP K30) (E1201)
Maize starch
Crospovidone
Microcrystalline cellulose
Colloidal anhydrous silica,
Magnesium stearate (E572)
Tablet coat
Hypromellose
Polyethylene glycol 400
6.2 Incompatibilities
None
6.3 Shelf life
36 months
6.4 Special precautions for storage
No special storage conditions required.
6.5 Nature and contents of container
Metronidazole 500 mg Tablets are available in blisters packs made up of aluminium and PVC foil.
Pack sizes: 14, 15, 21 and 100 tablets. Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
7 MARKETING AUTHORISATION HOLDER
Dawa Limited,
5 Sandridge Close,
Harrow, Middlesex,
HA1 1XD, UK.
8 MARKETING AUTHORISATION NUMBER(S)
PL 30684/0309
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
10/02/2020
10 DATE OF REVISION OF THE TEXT
08/04/2026